Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial

IMPORTANCE: Migraine is a disabling neurological disease characterized by severe headache attacks. Treatment options reduce migraine frequency for many patients, but adverse effects lead to discontinuation in many patients. OBJECTIVE: To demonstrate that galcanezumab is superior to placebo in the pr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JAMA Neurol
Egile Nagusiak: Stauffer, Virginia L., Dodick, David W., Zhang, Qi, Carter, Jeffrey N., Ailani, Jessica, Conley, Robert R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Medical Association 2018
Gaiak:
Original Investigation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143119/
https://ncbi.nlm.nih.gov/pubmed/29813147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2018.1212
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak